Idex Corp. price target lowered to $210 from $212 at Oppenheimer

Oppenheimer lowered the firm’s price target on Idex Corp. (IEX) to $210 from $212 and keeps an Outperform rating on the shares. The firm recently toured the company’s Rochester, NY Life Sciences Optics Center of Excellence, also meeting with Health & Science Technologies Group Executive Tara Tereso. Oppenheimer came away with a greater appreciation of IH&S differentiation and growth potential, as well as a stronger understanding of Idex’s integrated growth strategy and related value-creation runway.